18F-fluorodeoxyglucose-positron emission tomography in evaluation of primary cutaneous lymphoma

British Journal of Dermatology

Volumn 155, Issue 2, 2006, Pages 357-363

  Kumar, R ^a,b   Xiu, Y ^a   Zhuang, H M ^a   Alavi, A ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

18F fluorodeoxyglucose positron emission tomography; B cell non Hodgkin lymphoma; Positron emission tomography; Primary cutaneous lymphoma; T cell non Hodgkin lymphoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; B CELL LYMPHOMA; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAMPLE SIZE; SKIN BIOPSY; SKIN LYMPHOMA; SKIN METASTASIS; CUTANEOUS T CELL LYMPHOMA; EVALUATION; MIDDLE AGED; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SKIN TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33745917122     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07367.x     Document Type: Article

References (28)

1. Prince HM, McCormack C, Ryan G et al. Management of the primary cutaneous lymphomas. Australas J Dermatol 2003; 44:227-40.
2. Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105:3768-85.
3. Siegel RS, Pandolfino T, Guitart J et al. Primary cutaneous T-cell lymphoma: review and current concepts. J Clin Oncol 2000; 18:2908-25.
4. Hayes TG, Rabin VR, Rosen T, Zubler MA. Hodgkin's disease presenting in the skin: case report and review of the literature. J Am Acad Dermatol 1990; 22:944-7.
5. Zucca E, Cavalli F. Extranodal lymphomas. Ann Oncol 2000; 11 (Suppl. 3):219-22.
6. Pandolfino TL, Siegel RS, Kuzel TM et al. Primary cutaneous B-cell lymphoma: review and current concepts. J Clin Oncol 2000; 18:2152-68.
7. Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer (EORTC). Blood 1997; 90:354-71.
8. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999; 40:418-25.
9. Santucci M, Pimpinelli N, Arganini L. Primary cutaneous B-cell lymphoma: a unique type of low-grade lymphoma. Clinicopathologic and immunologic study of 83 cases. Cancer 1991; 67:2311-26.
10. Kim YH, Chow S, Varghese A, Hoppe RT. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. Arch Dermatol 1999; 135:26-32.
11. 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas. J Am Acad Dermatol 2002; 47:623-8.
12. Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003; 30 (Suppl. 1):S42-55.
13. Moog F, Bangerter M, Diederichs CG et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997; 203:795-800.
14. Moog F, Bangerter M, Diederichs CG et al. Extranodal malignant lymphoma: detection with FDG PET vs. CT. Radiology 1998; 206:475-81.
15. 18F] 2-fluoro-D-2-deoxyglucose in primary cutaneous T-cell lymphomas. Haematologica 2004; 89:115-16.
16. Picardi M, Gennarelli N, Ciancia R et al. Randomized comparison of power Doppler ultrasound-directed excisional biopsy with standard excisional biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma. J Clin Oncol 2004; 22:3733-40.
17. Hussain R, Christie DR, Gebski V et al. The role of the gallium scans in primary extranodal lymphoma. J Nucl Med 1998; 39:95-8.
18. van den Anker-Lugtenburg PJ, Heule F, Vanhagen PM et al. Somatostatin receptor scintigraphy in cutaneous malignant lymphomas. J Am Acad Dermatol 1996; 34:985-93.
19. Kostakoglu L, Goldsmith SJ. Positron emission tomography in lymphoma: comparison with computed tomography and gallium-67 single photon emission computed tomography. Clin Lymphoma 2000; 1:67-74.
20. 18F]-FDG positron imaging in clinical management of lymphoma patients. Crit Rev Oncol Hematol 2001; 38:193-221.
21. 18F-FDGPET) for staging and follow-up of marginal zone B cell lymphoma. Oncology 2003; 64:336-40.
22. Elstrom R, Guan L, Baker G et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101:3875-6.
23. Hustinx R, Smith RJ, Benard F et al. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: a potential method to differentiate malignancy from inflammation and normal tissue in the head and neck. Eur J Nucl Med 1999; 26:1345-48.
24. Zhuang H, Pourdehnad M, Lambright ES et al. Dual time point F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001; 42:1412-17.
25. 18F-FDG in Hodgkin's disease for post-treatment evaluation. J Nucl Med 2003; 44:1225-31.
26. Cremerius U, Fabry U, Kroll U et al. Clinical value of FDG PET for therapy monitoring of malignant lymphoma - results of a retrospective study in 72 patients. Nuklearmedizin 1999; 38:24-30.
27. Berger M, Gould MK, Barnett PG. The cost of positron emission tomography in six United States Veterans Affairs hospitals and two academic medical centers. Am J Roentgenol 2003; 181:359-65.
28. Klose T, Leidl R, Buchmann I et al. Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography. Eur J Nucl Med 2000; 27:1457-64.